Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287364 · ClinicalTrials.gov registry record · Phase 3
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
A Phase 3 study of Perennial Allergic Rhinitis, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 6
- Study locations
NCT01287364 is a Phase 3 study of Perennial Allergic Rhinitis that has completed, run by Sumitomo Pharma America. The registered enrollment target is 185 participants, below the 565-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01287364, a Phase 3 study of Perennial Allergic Rhinitis, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of treatment satisfaction with and preference of an Internasal Corticosteroid (INCS)
Conditions Studied
Interventions
- DRUG ciclesonide hydrofluoroalkane (HFA) nasal aerosol
- DRUG mometasone nasal inhalation
Study Locations (6)
California
- Allergy and Asthma Associates of Southern California - Mission Viejo
- Allergy & Asthma Medical Group & Research Center A.P.C. - San Diego
Massachusetts
- Northeast Medical Research Associates, Inc. - North Dartmouth
Minnesota
- Clinical Research Institute - Minneappolis
New Jersey
- Princeton Center for Clinical Research - Skillman
Texas
- Sylvania Research Associates - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287364
The ClinicalTrials.gov registry entry for NCT01287364 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 565-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (67% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Perennial Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which ciclesonide hydrofluoroalkane (HFA) nasal aerosol is the first listed.
NCT01287364 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01287364 about?
NCT01287364 is a clinical study titled "Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis". This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of treatment satisfaction with and preference of an Internasal Corticosteroid ...
What is the current status of trial NCT01287364?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2011-02. Estimated completion is 2011-04.
What conditions does trial NCT01287364 study?
This clinical trial studies the following conditions: Perennial Allergic Rhinitis.
What interventions are being tested in trial NCT01287364?
The interventions under investigation include: ciclesonide hydrofluoroalkane (HFA) nasal aerosol (DRUG), mometasone nasal inhalation (DRUG).
Who is sponsoring clinical trial NCT01287364?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01287364 being conducted?
This trial has 6 study locations across California, Massachusetts, Minnesota, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Perennial Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 3
-
Safety Study of Olopatadine Nasal Spray
COMPLETED · Phase 3
-
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 4
-
Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.